<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02006888</url>
  </required_header>
  <id_info>
    <org_study_id>C13-04</org_study_id>
    <nct_id>NCT02006888</nct_id>
  </id_info>
  <brief_title>The Efficacy and Safety of IBI-10090 for the Treatment of Inflammation Associated With Cataract Surgery</brief_title>
  <official_title>The Efficacy and Safety of IBI-10090 for the Treatment of Inflammation Associated With Cataract Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ICON Bioscience Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ICON Bioscience Inc</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether IBI-10090 injection is effective in the
      treatment of inflammation associated with cataract surgery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A double blinded randomized trial to assess the efficacy and safety of IBI-10090, in two
      separate doses as compared to placebo (ATEC carrier only sans dexamethasone)
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Actual">October 2014</completion_date>
  <primary_completion_date type="Actual">October 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Anterior Chamber Cell Clearing</measure>
    <time_frame>Day 8</time_frame>
    <description>The primary efficacy outcome is anterior chamber cell clearing in the study eye at Day 8. The slit lamp examination for anterior chamber cells (ACC) is a recognized way to measure inflammation in the anterior chamber. During the slit lamp examination, the number of anterior chamber cells are quantified and graded: grade 0 (absent, 0 cells), grade 1 (1 to 5 cells), grade 2 (6 to 15 cells), grade 3 (16 to 30+ cells), or grade 4 (hypopyon). Anterior chamber cell clearing occurs when all the ACC are absent (grade 0).</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">394</enrollment>
  <condition>Inflammation</condition>
  <condition>Cataracts</condition>
  <arm_group>
    <arm_group_label>IBI-10090 low dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IBI-10090 low dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IBI-10090 med dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IBI-10090 med dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IBI-10090</intervention_name>
    <arm_group_label>IBI-10090 low dose</arm_group_label>
    <arm_group_label>IBI-10090 med dose</arm_group_label>
    <other_name>Dexycu</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. The patient must provide written informed consent by signing the Informed Consent
             approved by the Institutional Review Board (IRB).

          2. Male or female patients at least 40 years of age scheduled for unilateral cataract
             surgery by phacoemulsification with posterior chamber intraocular lens implantation.

          3. The patient must demonstrate best corrected visual acuity (BCVA) of 20/30-20/200 (with
             glare testing, if necessary) in the study eye and better than 20/200 in the fellow
             eye.

          4. The patient must be considered by the Investigator to have visual acuity potential
             greater than 20/30 in the study eye.

          5. The patient must have a corneal endothelial cell count by specular microscopy in the
             study eye of at least 2000 cells/mm2 with normal cell morphology.

          6. A female patient of childbearing potential (premenopausal by medical history) must
             have a negative pregnancy test on Day 0 and be using an effective method of birth
             control (although no birth control method is 100% effective, the following are
             considered effective means of contraception: surgical sterilization, use of oral
             contraceptives, barrier contraception using either a condom or diaphragm with
             spermicidal gel, an intrauterine device, or contraceptive hormone implant or patch)
             from Screening for the duration of the study.

          7. The patient must be willing and able to understand and comply with the study
             procedures and to communicate meaningfully with study personnel.

        Key Exclusion Criteria:

          1. Patients who have used any ocular, topical or oral corticosteroids within 7 days prior
             to Day 0.

          2. Patients who have received a periocular corticosteroid injection in the study eye in
             the 3 months prior to screening.

          3. Patients who have received any intravitreal corticosteroid delivery vehicle (e.g.,
             Retisert, Ozurdex, Iluvien) in the study eye at any time.

          4. Patients who anticipate requiring treatment with any corticosteroids by any route,
             except inhalation, during the study.

          5. Patients with an allergy or hypersensitivity to dexamethasone.

          6. Patients who are known steroid responders (corticosteroid-related intraocular pressure
             elevation in either eye).

          7. Patients who have used topical ocular NSAIDs in the study eye within 15 days prior to
             Day 0.

          8. Patients who have undergone prior intraocular (non-laser) surgery in the study eye
             within 6 months prior to screening.

          9. Patients who have undergone prior intraocular laser surgery in the study eye within 3
             months prior to screening.

         10. Patients with planned intraocular or laser surgery in the study eye for the duration
             of the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>howard franklin, md</last_name>
    <role>Study Director</role>
    <affiliation>ICON Bioscience Inc</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hull Eye Center</name>
      <address>
        <city>Lancaster</city>
        <state>California</state>
        <zip>93534</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 5, 2013</study_first_submitted>
  <study_first_submitted_qc>December 9, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 10, 2013</study_first_posted>
  <results_first_submitted>August 15, 2017</results_first_submitted>
  <results_first_submitted_qc>March 23, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">April 23, 2018</results_first_posted>
  <last_update_submitted>March 23, 2018</last_update_submitted>
  <last_update_submitted_qc>March 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Inflammation</keyword>
  <keyword>cataract surgery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Inflammation</mesh_term>
    <mesh_term>Cataract</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The first patient was enrolled into the study on 19 December 2013 and the last patient completed the study on 03 October 2014.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>IBI-10090 Low Dose</title>
          <description>IBI-10090 low dose
IBI-10090</description>
        </group>
        <group group_id="P2">
          <title>IBI-10090 Med Dose</title>
          <description>IBI-10090 med dose
IBI-10090</description>
        </group>
        <group group_id="P3">
          <title>Placebo</title>
          <description>Placebo
Placebo: Placebo</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="158"/>
                <participants group_id="P2" count="156"/>
                <participants group_id="P3" count="80"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="122"/>
                <participants group_id="P2" count="122"/>
                <participants group_id="P3" count="58"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="36"/>
                <participants group_id="P2" count="34"/>
                <participants group_id="P3" count="22"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>IBI-10090 Low Dose</title>
          <description>IBI-10090 low dose
IBI-10090</description>
        </group>
        <group group_id="B2">
          <title>IBI-10090 Med Dose</title>
          <description>IBI-10090 med dose
IBI-10090</description>
        </group>
        <group group_id="B3">
          <title>Placebo</title>
          <description>Placebo
Placebo: Placebo</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="158"/>
            <count group_id="B2" value="156"/>
            <count group_id="B3" value="80"/>
            <count group_id="B4" value="394"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                    <measurement group_id="B2" value="41"/>
                    <measurement group_id="B3" value="17"/>
                    <measurement group_id="B4" value="99"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="117"/>
                    <measurement group_id="B2" value="115"/>
                    <measurement group_id="B3" value="63"/>
                    <measurement group_id="B4" value="295"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="70" spread="9"/>
                    <measurement group_id="B2" value="70" spread="9"/>
                    <measurement group_id="B3" value="71" spread="9"/>
                    <measurement group_id="B4" value="70" spread="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="75"/>
                    <measurement group_id="B2" value="69"/>
                    <measurement group_id="B3" value="39"/>
                    <measurement group_id="B4" value="183"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="83"/>
                    <measurement group_id="B2" value="87"/>
                    <measurement group_id="B3" value="41"/>
                    <measurement group_id="B4" value="211"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="56"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="139"/>
                    <measurement group_id="B2" value="133"/>
                    <measurement group_id="B3" value="66"/>
                    <measurement group_id="B4" value="338"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="49"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="129"/>
                    <measurement group_id="B2" value="123"/>
                    <measurement group_id="B3" value="67"/>
                    <measurement group_id="B4" value="319"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="158"/>
                    <measurement group_id="B2" value="156"/>
                    <measurement group_id="B3" value="80"/>
                    <measurement group_id="B4" value="394"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Anterior Chamber Cell Clearing</title>
        <description>The primary efficacy outcome is anterior chamber cell clearing in the study eye at Day 8. The slit lamp examination for anterior chamber cells (ACC) is a recognized way to measure inflammation in the anterior chamber. During the slit lamp examination, the number of anterior chamber cells are quantified and graded: grade 0 (absent, 0 cells), grade 1 (1 to 5 cells), grade 2 (6 to 15 cells), grade 3 (16 to 30+ cells), or grade 4 (hypopyon). Anterior chamber cell clearing occurs when all the ACC are absent (grade 0).</description>
        <time_frame>Day 8</time_frame>
        <group_list>
          <group group_id="O1">
            <title>IBI-10090 Low Dose</title>
            <description>IBI-10090 low dose
IBI-10090</description>
          </group>
          <group group_id="O2">
            <title>IBI-10090 Med Dose</title>
            <description>IBI-10090 med dose
IBI-10090</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo
Placebo: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Anterior Chamber Cell Clearing</title>
          <description>The primary efficacy outcome is anterior chamber cell clearing in the study eye at Day 8. The slit lamp examination for anterior chamber cells (ACC) is a recognized way to measure inflammation in the anterior chamber. During the slit lamp examination, the number of anterior chamber cells are quantified and graded: grade 0 (absent, 0 cells), grade 1 (1 to 5 cells), grade 2 (6 to 15 cells), grade 3 (16 to 30+ cells), or grade 4 (hypopyon). Anterior chamber cell clearing occurs when all the ACC are absent (grade 0).</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="158"/>
                <count group_id="O2" value="156"/>
                <count group_id="O3" value="80"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99"/>
                    <measurement group_id="O2" value="103"/>
                    <measurement group_id="O3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>IBI-10090 Low Dose</title>
          <description>IBI-10090 low dose
IBI-10090</description>
        </group>
        <group group_id="E2">
          <title>IBI-10090 Med Dose</title>
          <description>IBI-10090 med dose
IBI-10090</description>
        </group>
        <group group_id="E3">
          <title>Placebo</title>
          <description>Placebo
Placebo: Placebo</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>Corneal decompensati</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="158"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Corneal decompensation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="158"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="156"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2.5</frequency_threshold>
        <default_vocab>eye pain</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="158"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="156"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>eye pain</sub_title>
                <counts group_id="E1" events="16" subjects_affected="16" subjects_at_risk="158"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="156"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Howard Franklin</name_or_title>
      <organization>IconBioscience</organization>
      <phone>2153961332 ext 215</phone>
      <email>hfranklin@iconbioscience.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

